Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis - BusinessNewsAsia.com - Business News Asia
4/27/2022 12:00:00 AM3 years 10 months ago
by Marie Jones
by Marie Jones
Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company deve…
Legend Capital’s portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Bi… [+2324 chars]
full article...